News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Li Ka Shing Foundation, Temasek Pump SGD12M to Advance Histotripsy Cancer Therapy Clinical Trials
The Li Ka Shing Foundation and Temasek Trust committed SGD12 million to introduce innovative non-invasive ultrasound histotripsy tumor treatment clinical trials to Singapore.The Na...
Reset
Send
The window will close in 5 seconds
Li Ka Shing Foundation, Temasek Pump SGD12M to Advance Histotripsy Cancer Therapy Clinical Trials
Close
Recommend
32
Positive
74
Negative
31
 
SHORT SELL
 
STOCK INFO

The Li Ka Shing Foundation and Temasek Trust committed SGD12 million to introduce innovative non-invasive ultrasound histotripsy tumor treatment clinical trials to Singapore.

The National Cancer Centre Singapore and the National University Cancer Institute, Singapore, will each receive a histotripsy system, being the first of its kind in Southeast Asia.

Related NewsHSBC Research Resumes Coverage of CKH with Rating Buy, Cuts TP to $53
The funding from the Li Ka Shing Foundation and Temasek Trust will also support clinical trials in Singapore for patients with liver, kidney, and pancreatic cancers, advancing regional cancer research and innovation.

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.